Works by Huaxiang Liu

Results: 44
    1

    Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.

    Published in:
    Clinical Rheumatology, 2022, v. 41, n. 10, p. 3005, doi. 10.1007/s10067-022-06199-8
    By:
    • Li, Jia;
    • Xue, Zhixin;
    • Wu, Zhenbiao;
    • Bi, Liqi;
    • Liu, Huaxiang;
    • Wu, Lijun;
    • Liu, Shengyun;
    • Huang, Xiangyang;
    • Wang, Yong;
    • Zhang, Yan;
    • Qi, Wufang;
    • He, Lan;
    • Dai, Lie;
    • Sun, Lingyun;
    • Li, Xiaomei;
    • Shuai, Zongwen;
    • Zhao, Yi;
    • Wang, Yanyan;
    • Xu, Jian;
    • Zhang, Hao
    Publication type:
    Article
    2

    Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.

    Published in:
    Clinical Rheumatology, 2022, v. 41, n. 3, p. 731, doi. 10.1007/s10067-021-05943-w
    By:
    • Su, Jinmei;
    • Li, Mengtao;
    • He, Lan;
    • Zhao, Dongbao;
    • Wan, Weiguo;
    • Liu, Yi;
    • Xu, Jianhua;
    • Xu, Jian;
    • Liu, Huaxiang;
    • Jiang, Lindi;
    • Wu, Huaxiang;
    • Zuo, Xiaoxia;
    • Huang, Cibo;
    • Liu, Xiumei;
    • Li, Fen;
    • Zhang, Zhiyi;
    • Liu, Xiangyuan;
    • Dong, Lingli;
    • Li, Tianwang;
    • Chen, Haiying
    Publication type:
    Article
    3
    4

    Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China.

    Published in:
    Emerging Microbes & Infections, 2021, v. 10, n. 1, p. 2303, doi. 10.1080/22221751.2021.2004864
    By:
    • Liu, Xiaoqing;
    • Zhang, Lifan;
    • Zhang, Fengchun;
    • Zeng, Xiaofeng;
    • Zhao, Yan;
    • Wang, Qian;
    • Liu, Shengyun;
    • Zuo, Xiaoxia;
    • Zhang, Zhiyi;
    • Wu, Huaxiang;
    • Chen, Sheng;
    • Li, Hongbin;
    • Zhu, Ping;
    • Wu, Lijun;
    • Qi, Wencheng;
    • Liu, Yi;
    • Zhang, Miaojia;
    • Liu, Huaxiang;
    • Xu, Dong;
    • Zheng, Wenjie
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points.

    Published in:
    Frontiers in Pharmacology, 2020, v. 11, p. N.PAG, doi. 10.3389/fphar.2020.606497
    By:
    • Su, Jinmei;
    • Li, Mengtao;
    • He, Lan;
    • Zhao, Dongbao;
    • Wan, Weiguo;
    • Liu, Yi;
    • Xu, Jianhua;
    • Xu, Jian;
    • Liu, Huaxiang;
    • Jiang, Lindi;
    • Wu, Huaxiang;
    • Zuo, Xiaoxia;
    • Huang, Cibo;
    • Liu, Xiumei;
    • Li, Fen;
    • Zhang, Zhiyi;
    • Liu, Xiangyuan;
    • Dong, Lingli;
    • Li, Tianwang;
    • Chen, Haiying
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.

    Published in:
    Arthritis Research & Therapy, 2022, v. 24, n. 1, p. 1, doi. 10.1186/s13075-022-02821-x
    By:
    • Zeng, Xiaofeng;
    • Liu, Ju;
    • Liu, Xiumei;
    • Wu, Lijun;
    • Liu, Yi;
    • Liao, Xiangping;
    • Liu, Huaxiang;
    • Hu, Jiankang;
    • Lu, Xin;
    • Chen, Linjie;
    • Xu, Jian;
    • Jiang, Zhenyu;
    • Lu, Fu-ai;
    • Wu, Huaxiang;
    • Li, Ying;
    • Wang, Qingyu;
    • Zhu, Jun;
    • the HLX01-RA03 Investigators;
    • Sun, Lingyun;
    • Wang, Meimei
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30

    Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.

    Published in:
    BioDrugs, 2020, v. 34, n. 3, p. 381, doi. 10.1007/s40259-020-00408-z
    By:
    • Su, Jinmei;
    • Li, Mengtao;
    • He, Lan;
    • Zhao, Dongbao;
    • Wan, Weiguo;
    • Liu, Yi;
    • Xu, Jianhua;
    • Xu, Jian;
    • Liu, Huaxiang;
    • Jiang, Lindi;
    • Wu, Huaxiang;
    • Zuo, Xiaoxia;
    • Huang, Cibo;
    • Liu, Xiumei;
    • Li, Fen;
    • Zhang, Zhiyi;
    • Liu, Xiangyuan;
    • Dong, Lingli;
    • Li, Tianwang;
    • Chen, Haiying
    Publication type:
    Article
    31

    A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

    Published in:
    Arthritis Research & Therapy, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13075-024-03375-w
    By:
    • Leng, Xiaomei;
    • Leszczyński, Piotr;
    • Jeka, Slawomir;
    • Liu, Shengyun;
    • Liu, Huaxiang;
    • Miakisz, Malgorzata;
    • Gu, Jieruo;
    • Kilasonia, Lali;
    • Stanislavchuk, Mykola;
    • Yang, Xiaolei;
    • Zhou, Yinbo;
    • Dong, Qingfeng;
    • Mitroiu, Marian;
    • Addison, Janet;
    • Rezk, Mourad F.;
    • Zeng, Xiaofeng
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38

    Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study.

    Published in:
    Rheumatology & Therapy, 2023, v. 10, n. 3, p. 757, doi. 10.1007/s40744-023-00544-2
    By:
    • Ye, Hua;
    • Liu, Shengyun;
    • Xu, Jian;
    • Chai, Kexia;
    • He, Dongyi;
    • Fang, Yongfei;
    • Xie, Qibing;
    • Liu, Huaxiang;
    • Liu, Ying;
    • Hua, Bingzhu;
    • Hu, Jiankang;
    • Zhang, Zhiyi;
    • Zhou, Mingxuan;
    • Zhao, Dongbao;
    • Li, Yan;
    • Jiang, Zhenyu;
    • Wang, Meimei;
    • Li, Jingyang;
    • Zhang, Zhuoli;
    • Li, Xiaomei
    Publication type:
    Article
    39
    40
    41
    42
    43
    44